LAUSR.org creates dashboard-style pages of related content for over 1.5 million academic articles. Sign Up to like articles & get recommendations!

Evolving evidence for immunosuppressants in COVID-19

Photo by lamoune from unsplash

In the section where the authors have stated the role of systemic corticosteroids, there are two more findings that are worth mentioning. First, a study found that SARS patients treated… Click to show full abstract

In the section where the authors have stated the role of systemic corticosteroids, there are two more findings that are worth mentioning. First, a study found that SARS patients treated with high-dose pulse therapy of methylprednisolone had systemic damage along with metabolic alterations at 12-years follow-up.2 Second, in the RECOVERY trial, treatment with a daily dose of dexamethasone for up to 10 days was associated with reduced 28-day mortality in COVID-19 patients with respiratory support.3 Ajay K Shukla Assistant professor, Department of Pharmacology, All India Institute of Medical Sciences, Saket Nagar, Bhopal, Madhya Pradesh, India

Keywords: pharmacology; evolving evidence; immunosuppressants covid; evidence immunosuppressants

Journal Title: Australian Prescriber
Year Published: 2021

Link to full text (if available)


Share on Social Media:                               Sign Up to like & get
recommendations!

Related content

More Information              News              Social Media              Video              Recommended



                Click one of the above tabs to view related content.